Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

M.M. Eggermont, Alexander; U. Blank, Christian; Mandalà, Mario; V. Long, Georgina; Atkinson, Victoria; Dalle, Stéphane; Haydon, Andrew; Lichinitser, Mikhail; Khattak, Adnan; S. Carlino, Matteo; Sandhu, Shahneen; Larkin, James; Puig, Susana; A. Ascierto, Paolo; Rutkowski, Piotr; Schadendorf, Dirk; H.T. Koornstra, Rutger; F. Hernandez‐Aya, Leonel; Maio, Michele; Johannes Maria van den Eertwegh, Alfonsus; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; Lorigan, Paul; Ibrahim, Nageatte; Marréaud, Sandrine; C. J. van Akkooi, Alexander; Suciu, Stefan; Robert, Caroline

doi:10.1056/nejmoa1802357

Public

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Published in New England Journal of Medicine • Apr 15, 2018

Authors:

Alexander M.M. Eggermont

Christian U. Blank

Mario Mandalà

Abstract

BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage ...

Subject

Pembrolizumab

Adjuvant

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!